Menu Search
Equities

Scandinavian ChemoTech AB

8V6:FRA

Scandinavian ChemoTech AB

Actions
  • Price (EUR)0.11
  • Today's Change-0.007 / -5.98%
  • Shares traded1.00k
  • 1 Year change-23.93%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Scandinavian ChemoTech AB grew revenues 496.62% from 473.00k to 2.82m while net income improved from a loss of 22.75m to a smaller loss of 21.09m.
Gross margin29.67%
Net profit margin-311.96%
Operating margin-298.93%
Return on assets-98.64%
Return on equity-197.97%
Return on investment-98.64%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Scandinavian ChemoTech AB fell by 4.93m. Cash Flow from Financing totalled 13.77m or 487.77% of revenues. In addition the company used 18.23m for operations while cash used for investing totalled 468.00k.
Cash flow per share-0.7202
Price/Cash flow per share--
Book value per share0.384
Tangible book value per share0.1270
More ▼

Balance sheet in SEKView more

Scandinavian ChemoTech AB uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.